MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova, Inc. announced reaching the target enrollment of 200 patients in the NIH-funded SEANOBI-ALS study assessing their investigational drug MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS). The Expanded Access Program provides treatment to patients ineligible for other trials, marking a significant milestone in patient engagement. …